Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Questions. Just how we should think about the translatability of the healthy volunteer data with KT-621 in second quarter and how that sort of how you expect that to derisk or relate to the patient setting, both in AD and in asthma? And specifically there, I guess, how should we be thinking about the relative level of stat expression from healthy to disease context?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : And it seems like there's an increasing number of STAT6 competitors or compounds entering the field kind of probably riding in your wave. Looking across the space there, I guess, how do you what -- other than being first in position -- having a leading position, how do you think about other ways of engaging the -- I guess what is very important by way of engaging the target that is -- will contribute to activity here? I guess, other approaches that are non-integrators, do you see being effective as also?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : You can try. Unidentified Participant (inaudible) Copenhagen, Denmark. So you mentioned EOE within the IBD space. Are you have any plans of going into either Crohn's or UC at some point?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Okay. We'll have to leave it there for time. Thanks very much, Nello.